CJC-1295 with DAC (Drug Affinity Complex) (10mg)

CJC-1295 with DAC Peptide (Lyophilized)

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionic acid)-NH2 Format: Sterile Lyophilized Powder (Vial) Conjugation: Drug Affinity Complex (DAC) Half-Life: 6 to 8 Days (Long-Acting) Purity: >99% (HPLC) Content: Available in 5mg and 10mg vials

Product Overview

CJC-1295 with DAC is a long-acting, tetrasubstituted analogue of Growth Hormone-Releasing Hormone (GHRH). It is distinguished by its unique Drug Affinity Complex (DAC) technology, which conjugates the peptide to serum albumin in vivo.

This conjugation extends the biological half-life from minutes to 6–8 days, creating a sustained elevation of Growth Hormone (GH) and IGF-1. This contrasts with "Modified GRF 1-29" (No DAC), which produces short, pulsatile spikes. This formulation is the primary subject of research for protocols requiring once-weekly administration and steady-state hormone elevation.

Mechanism of Action: In Vivo Bioconjugation

CJC-1295 utilizes a sophisticated "Trojan Horse" delivery system via the DAC moiety.

• Maleimide Linker: The peptide contains a maleimide group at the C-terminus that reacts specifically with Cysteine-34 on circulating serum albumin.

• Albumin Shielding: Once bound to albumin (67 kDa), the peptide is shielded from enzymatic degradation (DPP-IV) and is too large to be filtered by the kidneys.

• Sustained Release: The albumin conjugate circulates for weeks, providing continuous stimulation to the pituitary GHRH receptors.

Key Research Applications

1. Sustained GH & IGF-1 Elevation Clinical research (Teichman et al.) demonstrated that a single injection increases mean GH levels by 2- to 10-fold and sustains elevated IGF-1 for up to 28 days. This makes it ideal for research into chronic anabolism and lipolysis where daily injections are not feasible.

2. GHRH Knockout Rescue In GHRH knockout models, once-weekly administration of CJC-1295 was sufficient to normalize growth and induce pituitary hyperplasia (growth of somatotroph cells), proving its potent trophic effects.

3. Lipodystrophy & Metabolic Research Investigated for its ability to redistribute visceral fat and improve metabolic profiles in lipodystrophy models. The continuous GH pressure drives profound lipolysis via Hormone Sensitive Lipase (HSL).

Important Distinction: DAC vs. No DAC

• CJC-1295 with DAC: Half-life of 6-8 days. Causes a "bleed" or continuous wave of GH. Dosed weekly.

• Modified GRF 1-29 (No DAC): Half-life of 30 minutes. Causes distinct pulses. Dosed 3x daily.

• This listing is for the DAC (Long-Acting) variant.

Storage & Handling

• Physical State: Lyophilized (Freeze-Dried) White Powder.

• Storage (Lyophilized): Store at -20°C (Freezer). Stable for >24 months.

• Reconstitution:

  • Solvent: Bacteriostatic Water or Sterile Saline.

  • Solubility: Highly soluble.

• Storage (Reconstituted): Store at 4°C (Refrigerator). While more stable than native GHRH, use within 14-21 days to ensure the maleimide linker remains active for conjugation.

Disclaimer

FOR RESEARCH USE ONLY. This product is a chemical compound intended strictly for laboratory research and development. It is not approved by the FDA for clinical use, diagnostics, or therapeutic procedures in humans or animals. The physiological and toxicological properties of this chemical have not been fully investigated.